2025 Guidelines for the Evaluation and Management of Adults With Congenital Heart Disease
December 19, 2025
Brand Name :
Bevespi aerosphere
Synonyms :
Class :
Anti-cholinergic, Beta 2 agonists
Dosage Forms & Strengths
Inhalation aerosol
Formoterol 9mcg/ Glycopyrrolate inhaled 4.8mcg for each inhalation
Chronic Obstructive Pulmonary Disease (COPD)
Mouth spray
Orally inhaled
twice a day
Two inhalations (Formoterol 18mcg/ Glycopyrrolate inhaled 9 mcg for each inhalation)
Do not exceed two inhalations per day
may enhance the effects of the other by pharmacodynamic synergism
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
it enhances the serum potassium levels
it enhances the serum potassium levels
it enhances the serum potassium levels
may increase the QTc interval when combined
may decrease the effect of each other by unspecified interaction mechanism
may increase the QTc interval when combined
may increase the QTc interval when combined
it diminishes the serum potassium levels
may decrease the toxic effects of each other by sedation
may decrease the toxic effects of each other by sedation
may decrease the toxic effects of each other by sedation
may decrease the toxic effects of each other by sedation
may increase the QTc interval when combined
may decrease the toxic effects of each other by sedation
may decrease the toxic effects of each other by sedation
decreases the serum potassium levels
it decreases the serum potassium levels
may increase the QTc interval when combined
may increase the QTc interval when combined
may increase the QTc interval when combined
may diminish the effects through pharmacodynamic antagonism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may diminish the effects through pharmacodynamic antagonism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
Frequency defined:
1-10%
Anxiety
Influenza
Cough
Arthralgia
Muscle spasms
Acute sinusitis
Tooth abscess
Dizziness
Vomiting
Chest pain
Frequency not defined
Nausea
Hyperglycemia
Agitation
Palpitations
Sleep disturbance
Cardiac arrhythmias
Pregnancy consideration: Insufficient data is available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Patient information leaflet
Generic Name: Glycopyrrolate inhaled/formoterol
Pronounced: glye-koe-PYE-roe-late; for-MOH-te-rol
Why do we use Glycopyrrolate inhaled/formoterol?
It is used to treat chronic obstructive pulmonary disease, which includes emphysema and chronic bronchitis